Skip to main content

Table 3 Association between intake of at least one systemic antiherpetic drugs and incidence of dementia - Cox models. ‶Echantillon Généraliste des Bénéficiaires.″ 2009–2017

From: Antiherpetic drugs: a potential way to prevent Alzheimer’s disease?

  Adjusted modela
Events aHR 95% CI P-value
In all the subjects (n= 68291)
 All dementias 8883 0.90 0.82–0.99 0.03
 Alzheimer’s disease 5366 0.85 0.75–0.96 0.009
 Vascular dementia 1784 0.80 0.65–0.995 0.045
After exclusion of immunocompromised subjects, subjects with cancer or with an hospitalization related to herpesviruses (n=52254)
 All dementias 7044 0.84 0.75–0.94 0.002
 Alzheimer’s disease 4260 0.82 0.71–0.95 0.007
 Vascular dementia 1433 0.77 0.60–0.99 0.04
After carrying out a lag-time of 1 year (n= 68291)
 All dementias 8883 0.86 0.78–0.95 0.004
 Alzheimer’s disease 5366 0.78 0.68–0.90 0.001
 Vascular dementia 1784 0.87 0.691.09 0.23
After exclusion of participants with ≥ 2 deliveries of systemic AHDs per year of follow-up (n= 67904)
 All dementias 8856 0.91 0.83–0.997 0.04
 Alzheimer’s disease 5351 0.85 0.75–0.97 0.01
 Vascular dementia 1781 0.83 0.661.03 0.09
  1. Abbreviations: aHR adjusted hazard ratios, 95% CI 95% confidence interval, AHD antiherpetic drug
  2. aAdjustment for age at inclusion, sex, being beneficiary of a complementary health insurance for low-income people at inclusion, hypertension, diabetes, hypercholesterolemia, heart disease, stroke, intake of nonsteroidal anti-inflammatory drugs, systemic, or inhaled glucocorticoids the year before inclusion, number of different medications the year before inclusion, number of outpatient medical consultations the year before inclusion